Search

Guardant Health Inc

Slēgts

SektorsVeselības aprūpe

170.69 1.8

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

168.5

Max

170.69

Galvenie mērījumi

By Trading Economics

Ienākumi

-8.1M

-120M

Pārdošana

33M

335M

EPS

-0.89

Peļņas marža

-35.866

Darbinieki

2,490

EBITDA

-8.1M

-109M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+12.23% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.4B

22B

Iepriekšējā atvēršanas cena

168.89

Iepriekšējā slēgšanas cena

170.69

Ziņu noskaņojums

By Acuity

50%

50%

150 / 340 Rangs Healthcare

Guardant Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 19:16 UTC

Guardant Health Inc shares are higher today, despite pulling back from an intraday high. The stock remains well above its 20-day moving average.

2026. g. 20. aug. 23:46 UTC

Guardant Health Inc. shares advanced in after-market trading, remaining above their 20-day moving average amid broader market pressures from rising crude oil prices.

2026. g. 19. aug. 20:02 UTC

Guardant Health Inc shares are higher today, supported by high trading volume. The stock remains above its 20-day moving average and near recent highs.

2026. g. 14. aug. 19:36 UTC

Guardant Health Inc shares are lower amid broader market sentiment following disappointing retail sales data, which may impact consumer demand and Federal Reserve interest rate policy.

2026. g. 13. aug. 23:36 UTC

Guardant Health shares are higher in after-market trading, though no specific news was identified. Broader market sentiment may be influenced by unchanged producer prices.

2026. g. 12. aug. 19:51 UTC

News

Guardant Health shares are lower as insider sales raise investor concerns. Director Ian Clark sold 14,180 shares for $2.3 million earlier this month.

2026. g. 10. aug. 19:36 UTC

Guardant Health Inc. shares are higher today, remaining above their 20-day moving average amid rising oil prices driven by geopolitical tensions.

2026. g. 7. aug. 20:03 UTC

Guardant Health Inc shares are advancing amid strong momentum and high trading volume. Broader market gains coincide with a decline in Treasury yields.

2026. g. 6. aug. 19:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

2026. g. 3. aug. 19:56 UTC

News

Guardant Health shares are higher as Stifel and Canaccord maintain Buy ratings, raising price targets to $180 and $205, respectively.

2026. g. 31. jūl. 19:51 UTC

News
Social Media

Guardant Health Inc shares are trading higher as analysts raise price targets following strong second-quarter results and an upward revision of full-year revenue guidance.

2026. g. 30. jūl. 23:21 UTC

News
Social Media

Guardant Health reported second-quarter revenue of $335 million, raising 2026 guidance to $1.34 billion to $1.36 billion, boosting shares in after-market hours.

2026. g. 29. jūl. 18:54 UTC

Macro Event
News

Guardant Health Inc shares are higher as investors anticipate Q2 earnings on Thursday, following last quarter's revenue of $301.7 million, up 48.3% year-over-year.

2026. g. 28. jūl. 19:16 UTC

News

Guardant Health shares are lower despite a tribute video featuring Patrick Dempsey and RBC's note on potential coverage tailwinds for the company.

2026. g. 27. jūl. 19:36 UTC

News

Guardant Health Inc shares are lower, continuing a five-day decline despite a 48% year-over-year revenue increase and strong performance in the Shield segment.

2026. g. 24. jūl. 18:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Thursday's close and remaining below the 20-day moving average.

2026. g. 20. jūl. 20:02 UTC

News

Guardant Health Inc shares are lower today, continuing a decline since Friday amid mixed U.S. market performance and ongoing geopolitical tensions impacting investor sentiment.

Salīdzinājums

Cenas izmaiņa

Guardant Health Inc Prognoze

Cenas mērķis

By TipRanks

12.23% augšup

Prognoze 12 mēnešiem

Vidējais 191.56 USD  12.23%

Augstākais 215 USD

Zemākais 125 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Guardant Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

21

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

150 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat